The Administrative Core (Core A) will provide overall scientific leadership and governance for the CFAR. It will provide overall administration and coordination of all CFAR Cores, SWGs and activities, and will orchestrate communication among CFAR stakeholders (including CFAR faculty, community members, external and internal advisory boards, NIAID program staff, and UR institutional leadership). During our funding cycle as a Developmental CFAR (D-CFAR), this Core has developed an innovative approach to building multidisciplinary research collaborations (scientific """"""""speed dating""""""""). It has also conducted strategic planning that has addressed investigator needs, improved core services, created a new institutional partnership to enhance drug discovery research, and identified research opportunities that have resulted in new funding for young faculty. The Core will be responsible for: (1) setting policies and procedures for the CFAR;(2) providing transparent financial management and ensuring regulatory compliance;(3) overseeing all CFAR Cores, SWGs and activities;determining scientific priorities and resource allocation (including pilot awards);(4) organizing and coordinating key CFAR committees and advisory boards, as well as the annual CFAR retreat and NIH site visit;(5) maintaining open lines of communication between CFAR members, other stakeholders, and CFAR leadership;(6) ensuring that the CFAR is highly visible on campus, and has a voice in UR research policy and recruitment;(7) conducting regular, inclusive, strategic planning sessions that inform CFAR decision-making;(8) promoting internal and external research partnerships that result in new multidisciplinary collaborations;(9) ensuring that the CFAR effectively leverages unique research strengths at UR, thereby creating a distinctive scientific identity for itself;and (10) conducting innovative, rigorous programmatic evaluation that results in effective decision-making - leading to improved services and enhanced outcomes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI078498-07
Application #
8712924
Study Section
Special Emphasis Panel (ZAI1-UKS-A)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
7
Fiscal Year
2014
Total Cost
$342,772
Indirect Cost
$119,468
Name
Case Western Reserve University
Department
Type
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Brewer, Matthew G; DiPiazza, Anthony; Acklin, Joshua et al. (2017) Nanoparticles decorated with viral antigens are more immunogenic at low surface density. Vaccine 35:774-781
Morse, Diane S; Wilson, John L; McMahon, James M et al. (2017) Does a Primary Health Clinic for Formerly Incarcerated Women Increase Linkage to Care? Womens Health Issues 27:499-508
Lu, Xin; Johnson, Brent A (2017) Direct estimation for adaptive treatment length policies: Methods and application to evaluating the effect of delayed PEG insertion. Biometrics 73:981-989
Hilimire, Thomas A; Chamberlain, Jeffrey M; Anokhina, Viktoriya et al. (2017) HIV-1 Frameshift RNA-Targeted Triazoles Inhibit Propagation of Replication-Competent and Multi-Drug-Resistant HIV in Human Cells. ACS Chem Biol 12:1674-1682
Liu, Yuhang; Zhang, Jinfeng; Qiu, Xing (2017) Super-delta: a new differential gene expression analysis procedure with robust data normalization. BMC Bioinformatics 18:582
Kushwaha, Sameer; Lalani, Yasmin; Maina, Geoffrey et al. (2017) ""But the moment they find out that you are MSM…"": a qualitative investigation of HIV prevention experiences among men who have sex with men (MSM) in Ghana's health care system. BMC Public Health 17:770
Singh, Vir B; Singh, Meera V; Piekna-Przybylska, Dorota et al. (2017) Sonic Hedgehog mimetic prevents leukocyte infiltration into the CNS during acute HIV infection. Sci Rep 7:9578
Hayashi, Tsuyoshi; Jean, Maxime; Huang, Huachao et al. (2017) Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription. Antiviral Res 146:76-85
Antwi, Sampson; Yang, Hongmei; Enimil, Anthony et al. (2017) Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection. Antimicrob Agents Chemother 61:
Piekna-Przybylska, Dorota; Sharma, Gaurav; Maggirwar, Sanjay B et al. (2017) Deficiency in DNA damage response, a new characteristic of cells infected with latent HIV-1. Cell Cycle 16:968-978

Showing the most recent 10 out of 159 publications